EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction

Yue Guo iD, Haitao Hu, Wenbo Chen, Hao Yin, Jian Wu, Chang-Yu Hsieh, Qiaojun He, Ji Cao iD

Briefings in Bioinformatics · 22.01.2024 · 25 (2)

DOI: 10.1093/bib/bbae015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 10.02.2024. Verfasst von Yue Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang…. Hauptthemen laut MEDLINE: Drug Discovery, Lung Neoplasms. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Key Projects of Hangzhou Agricultural and Social Development Program, National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Discovering effective anti-tumor drug combinations is crucial for advancing cancer therapy. Taking full account of intricate biological interactions is highly important in accurately predicting drug synergy. However, the extremely limited prior knowledge poses great challenges in developing current computational methods. To address this, we introduce SynergyX, a multi-modality mutual attention network to improve anti-tumor drug synergy prediction. It dynamically captures cross-modal interactions, allowing for the modeling of complex biological networks and drug interactions. A convolution-augmented attention structure is adopted to integrate multi-omic data in this framework effectively. Compared with other state-of-the-art models, SynergyX demonstrates superior predictive accuracy in both the General Test and Blind Test and cross-dataset validation. By exhaustively screening combinations of approved drugs, SynergyX reveals its ability to identify promising drug combination candidates for potential lung cancer treatment. Another notable advantage lies in its multidimensional interpretability. Taking Sorafenib and Vorinostat as an example, SynergyX serves as a powerful tool for uncovering drug-gene interactions and deciphering cell selectivity mechanisms. In summary, SynergyX provides an illuminating and interpretable framework, poised to catalyze the expedition of drug synergy discovery and deepen our comprehension of rational combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoveryLung NeoplasmsHumansCatalysisCombined Modality TherapyResearch Design

Stichwörter der Autor:innen

combination therapydrug synergy predictionmulti-modalitymutual attentiontransformer

Autor:innen und Institutionen

  • Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 310058, Hangzhou, Zhejiang, China.
  • Polytechnic Institute, Zhejiang University, 269 Shixiang Road,310000, Hangzhou, Zhejiang, China.
  • Second Affiliated Hospital School of Medicine, School of Public Health, Zhejiang University, 866 Yuhangtang Road, 310058, Hangzhou, Zhejiang, China.
  • The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, 291 Fucheng Road, 310018, Hangzhou, Zhejiang, China.
  • College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, 310058, Hangzhou, Zhejiang, China.
  • Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, 866 Yuhangtang Road, 310058, Hangzhou, Zhejiang, China.

ORCID-Profile: Yue Guo, Ji Cao

Förderung

  • Key Projects of Hangzhou Agricultural and Social Development Program
  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation
  • Fundamental Research Funds for the Central Universities
  • Zhejiang Key R&D Program of China

Zitieren

APA

Guo, Y., Hu, H., Chen, W., Yin, H., Wu, J., Hsieh, C. Y., He, Q., & Cao, J. (2024). SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction. Briefings in Bioinformatics, 25(2). https://doi.org/10.1093/bib/bbae015

Vancouver

Guo Y, Hu H, Chen W, Yin H, Wu J, Hsieh CY, et al. SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction. Briefings in Bioinformatics. 2024;25(2). doi:10.1093/bib/bbae015

BibTeX
@article{Guo2024,
  author = {Guo, Yue and Hu, Haitao and Chen, Wenbo and Yin, Hao and Wu, Jian and Hsieh, Chang-Yu and He, Qiaojun and Cao, Ji},
  title = {SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction},
  journal = {Briefings in Bioinformatics},
  year = {2024},
  volume = {25},
  number = {2},
  doi = {10.1093/bib/bbae015}
}
Kostenlos starten →